Innoviva's IST unit posts 45% U.S. sales growth as NUZOLVENCE launches

Innoviva, Inc. reported financial results for the third quarter ended September 30, 2026, on November 4, 2026. CEO Pavel Raifeld highlighted that NUZOLVENCE, a first-in-class, single-dose oral antibiotic for uncomplicated urogenital gonorrhea, is now commercially available in the U.S.¹ The company said NUZOLVENCE's launch expands IST's commercial portfolio, with initial commercial efforts focused on establishing market access, distribution and dispensing infrastructure to support adoption over time.¹

On the regulatory front, updated 2026 guidance from the Infectious Diseases Society of America reaffirmed XACDURO (sulbactam/durlobactam for injection) with imipenem or meropenem as the preferred treatment for invasive carbapenem-resistant Acinetobacter baumannii infections, while recommending high-dose ampicillin-sulbactam only as temporary bridging therapy when XACDURO is unavailable.¹ Separately, the CDC's 2026 Antimicrobial Resistance Threats Report identified four pathogens in its highest threat category, two of which IST addresses with XACDURO and NUZOLVENCE.¹

IST also presented data at IDWeek 2026 for ZEVTERA and NUZOLVENCE, covering antimicrobial-resistant and difficult-to-treat infections.¹ XACDURO, ZEVTERA and NUZOLVENCE were named finalists for the 2026 Prix Galien USA Award in the "Best Pharmaceutical Product" category, the third consecutive year an IST product has received such recognition.¹

On guidance, management said the 45% year-over-year increase in U.S. net product sales to $43.3 million keeps the company on track to reach its 2026 guidance of at least $150 million in U.S. net product sales.¹

Cash and cash equivalents totaled $581.4 million as of September 30, 2026.¹ During the quarter, Innoviva repurchased 1,226,948 shares for $26.3 million under its $125 million buyback program, bringing cumulative repurchases to 3,829,116 shares for $82.7 million.¹